Table 2

Mean changes of secondary outcome measures from baseline

Secondary outcome measure, mean (SD)TimepointCT-P13
3 mg/kg
INX
3 mg/kg
p Value*
TJC (68 joints)Week 14−14.6 (11.1)−14.0 (11.4)0.559
Week 30−16.5 (11.7)−15.7 (12.6)0.458
SJC (66 joints)Week 14−10.9 (8.1)−10.2 (8.0)0.331
Week 30−12.4 (8.9)−11.4 (9.1)0.219
TJC (28 joints)Week 14−9.2 (6.4)−8.4 (6.0)0.149
Week 30−10.1 (6.7)−9.5 (6.4)0.378
SJC (28 joints)Week 14−7.8 (5.1)−7.2 (5.0)0.173
Week 30−8.8 (5.3)−7.9 (5.6)0.073
CDAIWeek 14−23.5 (12.4)−21.6 (11.6)0.076
Week 30−25.2 (13.3)−23.6 (13.0)0.182
SDAIWeek 14−24.0 (13.0)−22.4 (11.9)0.141
Week 30−25.8 (14.0)−24.4 (13.6)0.247
SF-36Week 14
Physical component summary7.5 (7.1)5.8 (6.8)0.007
Mental component summary6.6 (10.2)6.5 (10.4)0.925
Week 30
Physical component summary7.1 (7.9)6.5 (7.6)0.372
Mental component summary7.1 (10.0)6.6 (10.4)0.561
CRPWeek 14−0.6 (2.5)−0.8 (1.9)0.413
Week 30−0.6 (2.0)−0.8 (1.9)0.323
HAQWeek 14−0.6 (0.6)−0.5 (0.5)0.053
Week 30−0.6 (0.6)−0.5 (0.6)0.082
Patient's assessment of painWeek 14−29.5 (23.2)−27.2 (23.2)0.253
Week 30−29.5 (25.5)−27.8 (24.9)0.443
Patient global assessment of disease activityWeek 14−29.5 (22.1)−25.5 (24.4)0.057
Week 30−28.1 (25.9)−27.0 (25.6)0.658
Physician global assessment of disease activityWeek 14−35.4 (19.3)−33.7 (19.5)0.314
Week 30−35.6 (20.6)−35.3 (21.2)0.910
  • *Student's t test.

  • CDAI, Clinical Disease Activity Index; CRP, C reactive protein; HAQ, health assessment questionnaire; INX, innovator infliximab; SDAI, Simplified Disease Activity Index; SF-36, Short-Form Health Survey 36; SJC, swollen joint count; TJC, tender joint count.